Dr. Cornelis Natasha
ActiveSummary
Dr. Cornelis Natasha has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €695,232 and a net result of €112,657. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 50% of 20,604 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Activity
Specialist medical practice
NACE 86220
9th largest company by equity in Zedelgem, Health and social work sector1 site
Size
€1.1mtotal assets 2025
- Equity
- €695,232
- Profit
- €112,657
Turnover not published (micro format)
Structure
2025 accounts 2 days early1 of 3 deeds summarised
Why 93raises risk1 of the last 3 latelowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 2.40, cash €699,381Size: total assets €1.1mShow the evidence
Checked score
Score 2025
93
/ 100
Excellent
Probability in this band: under 0.55%
Financially better than 44% of its sector peers (NACE 86, micro)
Financial strength · tick = 2024
Strong
Solvency
88-12
equity 62.8% of total assets
Liquidity
89-7
short-term debt 28.4% · cash 63.1%
Profitability
81-4
return on assets 10.2%
Bankruptcy probability, 12 months
< 0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: < 0.1%
12-2024: < 0.1%● unchanged vs 11-2024
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: 0.1%▲ +0.1 percentage points vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025highest value
10-2025: < 0.1%▼ -0.1 percentage points vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026lowest value
09-2026: < 0.1%● unchanged vs 08-2026lowest value
10-2026: < 0.1%● unchanged vs 09-2026lowest value
Credit of up to €60,000 on 30-day terms is acceptable
Liquidity ample (current ratio 2.4, compared with 8.78 in 2024, above the usual 1.5; short-term debt: 28.4% and cash: 63.1% of total assets), and 37.2% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro): better than 50% on solvency, 72% on liquidity, 29% on profitability and 24% on growth.
The bankruptcy probability was computed on 24-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
2 days early
2024
27 days late
2023
49 days late
2022
77 days late
2021
5 days late
2020
5 days early
2019
4 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 21 days after the deadline; the sector median (NACE 86) for financial year 2024 is 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 27 August (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
25-10-2026 today31-12-2026 year end31-07-2027 deadline
- Annual accounts filedfinancial year 2025 · micro…
- Annual accounts filedfinancial year 2024 · micro…
- Liquidity more than doubledcurrent ratio 8.78
Financials · financial year 2025, micro format
In the rankings
#9 company by equity in Zedelgem, Health and social work sector
Equity
€695,232▼ 14.9%
2024 · €817,328
Total assets
€1.1m▲ 8.6%
2024 · €1.0m
Net result
€112,657▼ 17.0%
2024 · €135,736
Working capital
€438,633▼ 21.3%
2024 · €557,636
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result falls in 2025; 2025 is 19% below 2024.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Operating result€0.2m
2025
Net result€0.1m
2025
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€1.1m
2025
Equity€0.7m
2025
Debt€0.4m
2025
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€0.4m
2025
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
Return on assets (ROA)10.2%
2025
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency62.8%
2025
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio2.40
2025
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 86, Human health activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result€0.2m-€0.2m▼ 25.0%€0.2m▲ 27.4%€0.2m▲ 18.8%€0.3m▲ 29.8%€0.07m▼ 74.9%€0.2m▲ 161%€0.2m▼ 18.5%
Net result€0.1m-€0.1m▼ 25.3%€0.1mabove the sector's middle half▲ 30.5%€0.2mabove the sector's middle half▲ 18.3%€0.2mabove the sector's middle half▲ 29.1%€0.05mwithin the sector's middle half▼ 73.8%€0.1mabove the sector's middle half▲ 156%€0.1mwithin the sector's middle half▼ 17.0%
Equity€0.3m-€0.4m▲ 35.9%€0.5mabove the sector's middle half▲ 34.5%€0.6mabove the sector's middle half▲ 22.0%€0.8mabove the sector's middle half▲ 21.0%€0.7mabove the sector's middle half▼ 10.9%€0.8mabove the sector's middle half▲ 19.9%€0.7mabove the sector's middle half▼ 14.9%
Total assets€0.4m-€0.8m▲ 115%€0.9mabove the sector's middle half▲ 12.3%€1.0mabove the sector's middle half▲ 10.0%€1.1mabove the sector's middle half▲ 14.0%€1.0mabove the sector's middle half▼ 7.9%€1.0mabove the sector's middle half▼ 2.0%€1.1mabove the sector's middle half▲ 8.6%
Debt€0.09m-€0.4m▲ 361%€0.4m▼ 8.3%€0.4m▼ 6.4%€0.4m▲ 1.8%€0.4m▼ 1.6%€0.2m▼ 43.6%€0.4m▲ 104%
Working capital€0.2m-€0.3m▲ 53.2%€0.3mabove the sector's middle half▲ 26.3%€0.5mabove the sector's middle half▲ 32.0%€0.6mabove the sector's middle half▲ 28.2%€0.4mabove the sector's middle half▼ 27.5%€0.6mabove the sector's middle half▲ 32.4%€0.4mabove the sector's middle half▼ 21.3%
Solvency75.8%-48.0%▼ 27.8pp57.5%within the sector's middle half▲ 9.5pp63.8%within the sector's middle half▲ 6.3pp67.7%within the sector's middle half▲ 3.9pp65.5%within the sector's middle half▼ 2.2pp80.2%within the sector's middle half▲ 14.6pp62.8%within the sector's middle half▼ 17.4pp
Current ratio2.96-3.13▲ 0.163.75within the sector's middle half▲ 0.634.44within the sector's middle half▲ 0.684.42within the sector's middle half▼ 0.023.15within the sector's middle half▼ 1.278.78above the sector's middle half▲ 5.632.40within the sector's middle half▼ 6.38
Return on assets (ROA)36.5%-12.7%▼ 23.8pp14.8%within the sector's middle half▲ 2.1pp15.9%within the sector's middle half▲ 1.1pp18.0%within the sector's middle half▲ 2.1pp5.1%below the sector's middle half▼ 12.9pp13.3%within the sector's middle half▲ 8.2pp10.2%within the sector's middle half▼ 3.1pp
above
within
below
the middle half of NACE 86, Human health activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin not published: the micro format does not require them.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.1m
Fixed assets
€354,963 ▼ 9.1%
Current assets
€752,826 ▲ 19.6%
Equity and liabilities €1.1m
Equity
€695,232 ▼ 14.9%
Debt
€412,556 ▲ 104%
Debt's share of the balance-sheet total rises from 19.8% to 37.2%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€193,468▼
2024 · €229,109
Cash flow
€148,082▼
2024 · €170,895
Debt to equity
0.59▲
2024 · 0.25
ROE
16.2%▼
2024 · 16.6%
Interest coverage
66.49▼
2024 · over 100
Debt ≤ 1 year
€314,194▲
2024 · €71,705
Debt > 1 year
€98,363▼
2024 · €130,695
Income taxes
€46,476▼
2024 · €56,968
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 17,811 companies that looked in July 2024 the way this one looks now, 0.3% went bankrupt within 24 months and 96.5% are still going.
- Small
- 10 to 20 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
0.3%
went bankrupt
3.2%
stopped otherwise
96.5%
still going
For this company itself Checked computes a bankruptcy probability of < 0.1% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,475 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 17,811 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €17,561 | €25,258 | €25,968 | €26,963 | €26,963 | €23,026 | €35,159 | €35,425 | ▲ 0.8% |
| Other operating charges640/8 | - | - | - | €1,787 | €1,736 | €1,750 | €1,560 | €1,395 | ▼ 10.6% |
| Gross operating margin9900 | €219,937 | €183,722 | €219,155 | €257,191 | €325,301 | €99,225 | €230,669 | €194,863 | ▼ 15.5% |
| Operating profit (loss)9901 | €201,187 | €150,868 | €192,232 | €228,441 | €296,602 | €74,450 | €193,949 | €158,043 | ▼ 18.5% |
| Financial income75/76B | - | - | - | - | - | - | €129 | €4,000 | ▲ 31× |
| Recurring financial income75 | €0 | - | - | - | - | - | €129 | €4,000 | ▲ 31× |
| Financial charges65/66B | - | - | - | €2,001 | €1,748 | €1,521 | €1,374 | €2,910 | ▲ 112% |
| Recurring financial charges65 | €54 | €573 | €2,201 | €2,001 | €1,748 | €1,521 | €1,374 | €2,910 | ▲ 112% |
| Profit (loss) for the period before taxes9903 | €201,132 | €150,295 | €190,030 | €226,440 | €294,854 | €72,929 | €192,704 | €159,133 | ▼ 17.4% |
| Income taxes67/77 | €64,848 | €48,429 | €57,143 | €69,276 | €91,969 | €19,867 | €56,968 | €46,476 | ▼ 18.4% |
| Profit (loss) for the period9904 | €136,285 | €101,866 | €132,887 | €157,164 | €202,884 | €53,062 | €135,736 | €112,657 | ▼ 17.0% |
| Profit (loss) for the period to be appropriated9905 | €136,285 | €101,866 | €132,887 | €157,164 | €202,884 | €53,062 | €135,736 | €112,657 | ▼ 17.0% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €0.4m | €0.8m | €0.9m | €1.0m | €1.1m | €1.0m | €1.0m | €1.1m | ▲ 8.6% |
| Fixed assets21/28 | €0.1m | €0.4m | €0.4m | €0.4m | €0.4m | €0.4m | €0.4m | €0.4m | ▼ 9.1% |
| Tangible fixed assets22/27 | €0.1m | €0.4m | €0.4m | €0.4m | €0.4m | €0.4m | €0.4m | €0.4m | ▼ 9.1% |
| Land and buildings22 | - | - | - | €0.4m | €0.3m | €0.3m | €0.3m | €0.3m | ▼ 2.9% |
| Plant, machinery and equipment23 | - | - | - | - | - | - | €0.002m | €0.002m | ▼ 21.8% |
| Furniture and vehicles24 | - | - | - | €0.005m | - | €0.06m | €0.05m | €0.04m | ▼ 25.7% |
| Other tangible fixed assets26 | - | - | - | €0.05m | €0.04m | €0.03m | €0.02m | €0.003m | ▼ 80.3% |
| Current assets29/58 | €0.3m | €0.4m | €0.5m | €0.6m | €0.8m | €0.6m | €0.6m | €0.8m | ▲ 19.6% |
| Amounts receivable within one year40/41 | €0.03m | €0.03m | €0.05m | - | €0.001m | €0.07m | €0.1m | - | - |
| Trade receivables40 | - | - | - | - | €0.001m | €0.002m | - | - | - |
| Other amounts receivable41 | - | - | - | - | - | €0.07m | €0.1m | - | - |
| Current investments50/53 | - | - | - | - | - | - | €0.1m | - | - |
| Cash at bank and in hand54/58 | €0.2m | €0.4m | €0.4m | €0.4m | €0.5m | €0.5m | €0.4m | €0.7m | ▲ 87.7% |
| Deferred charges and accrued income490/1 | - | - | - | €0.1m | €0.2m | €0.05m | €0.05m | €0.05m | ▲ 14.3% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €0.4m | €0.8m | €0.9m | €1.0m | €1.1m | €1.0m | €1.0m | €1.1m | ▲ 8.6% |
| Equity10/15 | €0.3m | €0.4m | €0.5m | €0.6m | €0.8m | €0.7m | €0.8m | €0.7m | ▼ 14.9% |
| Contributions10/11 | €0.01m | €0.01m | - | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | = |
| Reserves13 | €0.3m | €0.4m | €0.5m | €0.6m | €0.7m | €0.6m | €0.8m | €0.7m | ▼ 15.5% |
| Non-distributable reserves130/1 | - | - | - | €0.002m | €0.002m | - | - | - | - |
| Reserves not available under the articles1311 | - | - | - | €0.002m | €0.002m | - | - | - | - |
| Distributable reserves133 | - | - | - | €0.6m | €0.7m | €0.6m | €0.8m | €0.7m | ▼ 15.5% |
| Profit (loss) carried forward14 | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | = |
| Amounts payable17/49 | €0.09m | €0.4m | €0.4m | €0.4m | €0.4m | €0.4m | €0.2m | €0.4m | ▲ 104% |
| Amounts payable after more than one year17 | - | €0.3m | €0.3m | €0.2m | €0.2m | €0.2m | €0.1m | €0.1m | ▼ 24.7% |
| Financial debts170/4 | - | - | - | €0.2m | €0.2m | €0.2m | €0.1m | €0.1m | ▼ 24.7% |
| Amounts payable within one year42/48 | €0.09m | €0.1m | €0.1m | €0.1m | €0.2m | €0.2m | €0.07m | €0.3m | ▲ 338% |
| Current portion of amounts payable after more than one year42 | - | - | - | €0.03m | €0.03m | €0.03m | €0.03m | €0.03m | ▲ 0.7% |
| Trade debts44 | €298 | €0.001m | €0.001m | €0.001m | €0.002m | €0.002m | €0.005m | €0.003m | ▼ 37.3% |
| Suppliers440/4 | - | - | - | €0.001m | €0.002m | €0.002m | €0.005m | €0.003m | ▼ 37.3% |
| Taxes, remuneration and social security45 | - | - | - | €0.03m | €0.04m | €0.004m | €0.01m | €0.02m | ▲ 56.7% |
| Taxes450/3 | - | - | - | €0.03m | €0.04m | - | €0.007m | €0.01m | ▲ 82.2% |
| Remuneration and social security454/9 | - | - | - | €0.003m | €0.003m | €0.004m | €0.003m | €0.003m | ▲ 1.1% |
| Other amounts payable47/48 | - | - | - | €0.06m | €0.09m | €0.2m | €0.02m | €0.3m | ▲ 974% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €136,285 | €101,866 | €132,887 | €157,164 | €202,884 | €53,062 | €135,736 | €112,657 | ▼ 17.0% |
| + Depreciation and write-downs630 | €17,561 | €25,258 | €25,968 | €26,963 | €26,963 | €23,026 | €35,159 | €35,425 | ▲ 0.8% |
| Operating cash flow (approximation) | €153,846 | €127,123 | €158,856 | €184,127 | €229,847 | €76,088 | €170,895 | €148,082 | ▼ 13.3% |
| Investment in fixed assets (approximation) | - | -€321,739 | -€56,265 | €0 | €0 | -€67,484 | -€2,277 | €0 | - |
| Change in cash | - | €132,516 | €46,278 | €33,604 | €59,785 | -€9,039 | -€124,714 | €326,854 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 11 filings with the National Bank
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | micro format | 29-07-2026 | 2026-00357397 |
| 31-12-2024 | micro format | 27-08-2025 | 2025-00470151 |
| 31-12-2023 | micro format | 18-09-2024 | 2024-00468229 |
| 31-12-2022 | micro format | 16-10-2023 | 2023-00487990 |
| 31-12-2021 | micro format | 05-08-2022 | 2022-20274358 |
| 31-12-2020 | micro format | 26-07-2021 | 2021-40300534 |
| 31-12-2019 | micro format | 27-07-2020 | 2020-37700434 |
| 31-12-2018 | micro format | 29-07-2019 | 2019-43300033 |
| 31-12-2017 | micro format | 26-07-2018 | 2018-40400097 |
| 31-12-2016 | micro format | 11-07-2017 | 2017-30500014 |
Similar companies · same sector, comparable size
DOKTER KATTY BOURGOIGNIE
BE 0458.551.167
Oostende · equity €695,301
FACE CLINIC
BE 0637.987.905
Waterloo · equity €695,399
RADONC
BE 1009.101.292
Gent · equity €694,796
BIJVENNE PROPERTIES
BE 0474.208.353
Hasselt · equity €694,737
Dr. Marc Claessens
BE 0832.634.142
Schilde · equity €695,896
Of the 16,582 active companies whose main activity is specialist medical practice (NACE 86220), figures are known for 8,113. 6,156 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Directors
No directors read yet: 1 of 3 Gazette acts processed. See the directors and other office holders in the KBO →
Owners and capital
Capital and shareholders
Capital over the years
- 23-10-2023 Capital stated in the deed · 100 shares
Group and network
Connections & network
No directors read yet: 1 of 3 Gazette acts processed.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
29-07
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
27-08
NBB filing
Annual accounts filed
financial year 2024 · micro format · 27 days late
2024
31-12
Financial
Liquidity more than doubledcurrent ratio 8.78
Current ratio from 3.15 to 8.78; short-term debt falls from €195,987 to €71,705.
18-09
NBB filing
Annual accounts filed
financial year 2023 · micro format · 49 days late
2023
31-12
Financial
Weakest financial yearnet €53,062 ▼73.8%
Net result drops to €53,062, the lowest in the series; recovery starts the following year.
23-10
Gazette deed
Amendment of the articles · Legal-form change · MiscellaneousRegistered office clause · Power of attorney · Capital conversion8 facts ▸
Gazette deed
Amendment of the articles · Legal-form change · Miscellaneous
Registered office clause · Power of attorney · Capital conversion8 facts ▸
- Registered office clause, “Torhoutsesteenweg 147,8210 Zedelgem” (deed in Dutch)
- Power of attorney
- Power of attorney, Pieter Van Hoestenberghe
- General meeting, 06-10-2023
- Capital conversion, “automatisch, van rechtswege” (deed in Dutch)
- Amendment of the articles
- Legal-form conversion, “besloten vennootschap” (deed in Dutch)
- Capital
16-10
NBB filing
Annual accounts filed
financial year 2022 · micro format · 77 days late
2022
31-12
Financial
Highest result from 2018 to 2025net €202,884 ▲29.1%
Operating result €296,602, net result €202,884, both a record.
05-08
NBB filing
Annual accounts filed
financial year 2021 · micro format · 5 days late
2021
26-07
NBB filing
Annual accounts filed
financial year 2020 · micro format
2020
31-12
Financial
Equity above €500,000equity €518,135 ▲34.5%
A profit in every financial year since 2018 builds equity to €518,135.
27-07
NBB filing
Annual accounts filed
financial year 2019 · micro format
Show earlier events
2019
29-07
NBB filing
Annual accounts filed
financial year 2018 · micro format
2018
26-07
NBB filing
Annual accounts filed
financial year 2017 · micro format
2017
11-07
NBB filing
Annual accounts filed
financial year 2016 · micro format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 11 annual accounts filed, the latest 10 are here; all 11 are under Financials.
1 of 3 deeds read
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Register details
Identification
Legal formPrivate limited company
Founded19-02-2015
Financial year end31-12
Activities, NACEBEL 2025
86220Specialist medical practice
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
86995Nutrition and dietetics services
E-invoicing
Not found in the Peppol Directory
No listing in the Peppol Directory under this enterprise or VAT number. That proves nothing: being listed there is voluntary.
What can you do?
Try sending from your invoicing software; if that fails, ask the customer whether they already receive via Peppol.
If the customer is not ready yet, you may send the invoice another way, for example as a PDF; if you send it electronically, you need their agreement on a secure channel. The invoice remains valid; it is the customer, not you, who risks a penalty. FPS Finance
If you follow this company, Checked tells you the day it appears in the Peppol register.
Register as of 24 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
Location & real-estate footprint
Registered office, Zedelgem · 1 establishment unit since 2015
Ground area
974 m²
Building footprint
237 m²
Building volume
1,539 m³
Parcel 31040F1518/00K000, Flanders · tallest building 9.0 m. Linked by address, not a title deed.
2
companies at this address
See who is registered here
1 establishment unit
Cornelis Natasha
since 2015unit no. 2.239.712.479
1 parcel
Flanders
1
(100%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 31040F1518/00K000 | Flanders | 974 m² | 1 · 237 m² | 9.0 m · 2 |
How the parcels are linked
Good to know
The parcel matches the address exactly.
Articles of association
What the company does
- PurposeThe activities the company may carry out under its articles.
- “In binnen -en buitenland,voor eigen rekening of voor rekening van derden het uitoefenen van de geneeskunde door de arts-aandeelhouder op het…” (deed in Dutch)
16 activities (deed in Dutch)
- In binnen -en buitenland,voor eigen rekening of voor rekening van derden het uitoefenen van de geneeskunde door de arts-aandeelhouder op het gebied van de oncologie,dit alles rekening houdend met de Medische Deontologie qua uitoefening van de geneeskunst,zo onder meer betreffende het beroepsgeheim.
- De geneeskunde zal enkel door de arts-aandeelhouder of artsen-aandeelhouders uitgeoefend worden en geenszins door de vennootschap.
- De beroepsaansprakelijkheid van de arts-aandeelhouder of artsen-aandeelhouders is onbeperkt.
- Alle inkomsten voortvloeiend uit de ingebrachte medische activiteit worden geïnd voor en door de vennootschap,zoals alle uit de medische activiteit voortvloeiende uitgaven door de vennootschap worden vereffend.
- Het inrichten van algemene diensten en een medisch secretariaat in het bijzonder die nuttig of nodig zijn voor de uitoefening van voormelde activiteit;
- De aankoop,het huren en/of leasen van alle medische apparatuur en begeleidende accommodaties,inclusief gebouwen,kortom van een volledige materiële infrastructuur om deze ter beschikking te stellen van de arts-aandeelhouder(s);
- Het scheppen van de mogelijkheden om de arts-aandeehouder(s) toe te laten zich verder te bekwamen in voormelde medische discipline,dit teneinde een kwalitatief hoogstaande praktijkuitoefening mogelijk te maken.
- Het verstrekken van informatie en/of onderricht inzake oncologie en dit in de breedste betekenis van het woord,zonder dat dit de vorm van een aanvullende commerciële activiteit mag aannemen.
- De vennootschap mag beleggen in roerende of onroerende goederen of mag haar middelen investeren,dit als bijkomstig voorwerp zonder evenwel het burgerlijk karakter van de vennootschap aan te tasten.
- In geval de vennootschap meerdere aandeelhouders telt dienen dan wel de modaliteiten van een akkoord over het investeringsbeleid te worden bepaald.
- Het beleggen of investeren van haar middelen mag gefinancierd worden door leningen.
- De vennootschap ontvangt rechtstreeks verschuldigde honoraria en dit voor eigen rekening.
- Zij mag deelnemen in alle ondernemingen die een gelijkaardig voorwerp nastreven maar overeenkomsten die artsen niet mogen afsluiten met andere artsen of met derden zullen ook door de vennootschap niet mogen afgesloten worden.
- De vennootschap kan deelnemen in kostenassociaties of middelenvennootschappen van artsen.
- De vennootschap kan tevens lid zijn van een vereniging zonder winstgevend doel van artsen.
- Dit alles rekening houdend met de Medische Deontologie en na voorafgaandelijke goedkeuring door de Provinciale Raad van de Orde van Artsen.
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- Dr. Cornelis Natasha
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaams Gewest, enkel besluit bestuursorgaan” (deed in Dutch)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- Each director alone
- Board ruleHow the board is made up, meets and takes decisions.
- “Één of meer bestuurders, Artikel 14” (deed in Dutch)“Vergoeding bestuurder, Artikel 16” (deed in Dutch)
Capital, shares and profit
- Kind of sharesWhich classes of shares exist and what rights each class carries.
- “Op naam, register van aandelen op naam met vermeldingen WVV” (deed in Dutch)
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- “Overdracht van aandelen onder de levenden, Artikel 9” (deed in Dutch)“Slechts overgaan op straffe van nietigheid aan andere arts die voldoet aan voorwaarden, overgang van aandelen wegens overlijden” (deed in Dutch)
- Share issue ruleHow and by whom new shares can be issued.
- “Inbreng in geld met uitgifte nieuwe aandelen-recht van voorkeur, per e-mail of bij ontbreken e-mailadres per gewone post op dezelfde dag als…” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Last Saturday of June at 10:00
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- “Algemene vergadering, vereist voor statutenwijziging” (deed in Dutch)
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Bestuurder(s) in functie krachtens statuten” (deed in Dutch)